查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992447

癌症影像系統市場：按產品類型、應用、技術和最終用戶分類－2026-2032年全球市場預測

Cancer Imaging System Market by Product Type, Application, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症影像系統市場價值將達到 192.4 億美元，到 2026 年將成長至 200.7 億美元，到 2032 年將達到 284.5 億美元，複合年成長率為 5.74%。

主要市場統計數據
基準年 2025 192.4億美元
預計年份：2026年 200.7億美元
預測年份 2032 284.5億美元
複合年成長率 (%) 5.74%

針對當前癌症影像學面臨的關鍵挑戰，制定了一個全面的框架，重點在於診斷準確性、工作流程整合以及臨床領導者的策略投資重點。

現代腫瘤學領域對兼具診斷準確性和操作效率的影像系統提出了更高的要求。電腦斷層掃描 (CT)、磁振造影(MRI)、混合成像模式以及人工智慧驅動的工作流程的進步，正在改變臨床醫生檢測、分期和後續觀察惡性腫瘤的方式。放射科團隊和醫院管理者如今在評估影像投資時，不僅關注影像質量，還關注互通性、處理能力、病患舒適度以及透過多學科協作對後續治療路徑的影響。

影像技術、電腦輔助增強技術和護理路徑整合的進步正在重塑腫瘤影像診斷工作流程和採購策略。

癌症影像領域正經歷一場變革，這場變革由三大並行因素驅動：影像技術創新、電腦輔助和診療路徑整合。影像技術創新不斷提升CT和MRI平台的空間和時間解析度，而混合系統和檢測器技術的進步則縮短了掃描時間並提高了病灶的可見度。同時，人工智慧和3D視覺化工具等電腦輔助手段正在提高診斷的一致性，並透過提高病灶檢出率、自動化定量測量和標準化機構間報告，加快決策速度。

到 2025 年，我們將重組醫療影像供應商的採購、資金籌措和生命週期規劃，評估價格調整帶來的採購壓力和供應鏈彈性策略。

2025年新關稅措施的實施將加強對醫療影像生態系統供應鏈的審查力度，促使採購經理重新評估零件來源、製造地和整體擁有成本假設。進口影像零件和資本設備的關稅將給採購預算帶來上行壓力，迫使採購者重新考慮維護策略、延長設備更換週期，並探索其他資金籌措結構以減輕眼前的財務負擔。這種財務壓力也普遍推動企業考慮在地化生產和供應網路，以降低跨境貿易政策波動帶來的風險。

需要詳細的細分見解，將產品類型、臨床應用、底層技術和最終用戶優先順序連結起來，以幫助選擇治療方式和服務模式設計。

了解細分市場的細微差別對於使產品選擇和服務模式與臨床和營運目標保持一致至關重要。就產品類型而言，電腦斷層掃描 (CT) 產品涵蓋範圍廣泛，從針對高解析度局部影像最佳化的錐狀射束CT，到提高時間解析度的雙多切面CT，再到兼顧速度和影像品質的多層螺旋 CT 系統。同時，數位放射線選項包括 CCD（電荷耦合元件）和平板檢測器技術，這些技術會影響劑量效率和工作流程整合。磁振造影(MRI) 提供封閉式系統（優先考慮高磁場下的診斷清晰度）、專用於肌肉骨骼成像的肢體 MRI 系統以及提高患者舒適度的開放式 MRI 解決方案。正子斷層掃描 (PET) 的差異化體現在 PET-CT 混合系統（整合解剖和代謝數據）和 PET-MRI 混合系統（結合卓越的軟組織對比和分子成像）。超音波診斷透過多普勒分析進行血管評估，透過2D影像進行常規評估，透過3D或四維分析支援體積評估和手術指導，從而不斷滿足各種臨床需求。

供應商的打入市場策略受到區域採用率差異、不同的醫療保健系統、法規環境和基礎設施優先事項的影響。

區域趨勢對整個癌症影像領域的普及曲線、供應商策略和服務交付模式都產生了顯著影響。在美洲，需求主要由整合醫療系統和大規模醫院網路驅動，這些系統和網路強調互通性、清晰的報銷機制和全生命週期服務合約。製造商通常會與當地服務供應商建立策略合作夥伴關係，以確保運作並支援複雜混合系統的部署。歐洲、中東和非洲（EMEA）地區法規環境和採購機制的多樣性導致了不同的普及路徑。該地區通常呈現出一種平衡：一方面是集中式學術機構推動早期普及，另一方面是分散式實踐優先考慮成本效益高的模式和模組化升級。同時，地緣政治因素和基礎設施投資的不平衡可能會加速人們對移動和擴充性影像解決方案的興趣。

透過結合卓越的硬體、軟體生態系統以及優先考慮臨床檢驗和營運連續性的服務模式，實現了競爭優勢。

產業相關人員正透過整合硬體卓越、軟體服務、數據分析和全面維護計劃的整合生態系統來實現差異化競爭。成熟的成像設備製造商持續投資於檢測器技術、磁鐵設計和混合模態工程，同時加速推進人工智慧演算法和視覺化套件的夥伴關係開發和內部研發，以提供超越影像生成的價值。同時，越來越多專注於人工智慧驅動的偵測、工作流程調整和雲端原生影像管理的專業技術公司，正給傳統供應商帶來越來越大的壓力，迫使其擴展軟體和服務組合。

為供應商和服務提供者制定可操作的策略重點，重點在於模組化平台、檢驗的人工智慧、靈活的採購和具有彈性的區域服務結構。

產業領導企業可以透過採取多項相互關聯的策略，採取果斷行動，確保充分利用不斷變化的臨床需求和政策變化。首先，他們應優先考慮模組化產品架構和軟體可升級平台，使客戶能夠在不完全更換硬體的情況下延長系統壽命並採用新的分析功能。其次，他們應投資於經過臨床檢驗的人工智慧工具和嚴謹的多中心研究，以證明其在病灶檢測、報告一致性和工作流程效率方面能夠帶來可衡量的改進，從而簡化監管核准流程並促進客戶接受。

結合相關人員訪談、臨床文獻綜述和技術比較評估的透明混合方法，可以獲得有關診斷成像的實用見解。

本研究整合了一手和二手訊息，旨在得出循證見解和實用建議。一手資訊透過臨床放射科醫師、影像中心主任、採購負責人和醫療設備服務經理的結構化訪談收集，以了解實際操作、影像模式優先順序和採購限制。這些定性資訊與技術文獻、同行評審的臨床研究、監管公告和製造商的產品規格進行交叉比對，以確保與最新的臨床證據和器械性能聲明保持一致。

結論強調了整合的必要性，即使影像能力與臨床路徑、採購的實用性以及已證實的患者獲益相一致。

隨著早期檢測、精準分期和個人化治療方案在癌症治療中變得日益重要，影像系統將繼續在多學科腫瘤臨床流程中發揮核心作用。先進的影像硬體、混合成像技術和運算分析的融合正在重塑診斷能力和操作預期。專注於互通性、檢驗的計算工具和靈活服務模式的醫療服務提供者和供應商將更有能力將技術進步轉化為可衡量的臨床效益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 癌症影像系統市場：依產品類型分類

  • 電腦斷層掃描
    • 錐狀射束CT
    • 雙源CT
    • 多切面CT
  • 數位X光成像
    • 電荷耦合幾何
    • 平板檢測器
  • 磁振造影
    • 閉式磁振造影
    • 四肢磁振造影
    • 開放式磁振造影
  • 正子斷層掃描
    • PET-CT
    • PET MRI
  • 超音波
    • 多普勒分析
    • 3D/4D 分析
    • 2D分析

第9章 癌症影像系統市場：依應用領域分類

  • 乳癌
  • 結腸癌
  • 肺癌
  • 攝護腺癌

第10章 癌症影像系統市場：依技術分類

  • 人工智慧
    • 電腦輔助檢測
    • 電腦輔助診斷
    • 工作流程管理
  • 造影影像診斷
    • CT造影劑
    • 磁振造影劑
    • 超音波造影
  • 混合成像
    • PET-CT混合
    • PET-MRI混合
    • SPECT-CT混合
  • 3D可視化
    • 最大強度投影
    • 表面渲染
    • 體繪製

第11章 癌症影像系統市場：依最終用戶分類

  • 學術研究機構
  • 診所
  • 診斷影像中心
  • 醫院

第12章 癌症影像系統市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 癌症影像系統市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癌症影像系統市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國癌症影像系統市場

第16章：中國腫瘤影像系統市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agfa-Gevaert NV
  • Agilent Technologies Inc.
  • Analogic Corporation
  • Barco NV
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Bracco Imaging SpA
  • Canon Medical Systems Corporation
  • Carestream Health Inc.
  • Danaher Corporation
  • Delphinus Medical Technologies Inc.
  • Elekta AB
  • Esaote SpA
  • F. Hoffmann-La Roche Ltd.
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies Inc.
  • Hitachi, Ltd.
  • Hologic Inc.
  • IBA Ion Beam Applications SA
  • Illumina Inc.
  • Konica Minolta Inc.
  • Koninklijke Philips NV
  • Lantheus Holdings Inc.
  • Samsung Medison Co., Ltd.
  • Siemens Healthineers AG
Product Code: MRR-3204321AF6C5

The Cancer Imaging System Market was valued at USD 19.24 billion in 2025 and is projected to grow to USD 20.07 billion in 2026, with a CAGR of 5.74%, reaching USD 28.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.24 billion
Estimated Year [2026] USD 20.07 billion
Forecast Year [2032] USD 28.45 billion
CAGR (%) 5.74%

Comprehensive framing of current cancer imaging imperatives emphasizing diagnostic precision, workflow integration, and strategic investment priorities for clinical leaders

The contemporary oncology landscape demands imaging systems that combine diagnostic precision with operational efficiency. Advances across computed tomography, magnetic resonance imaging, hybrid modalities, and AI-driven workflows are changing how clinicians detect, stage, and monitor malignancies. Radiology teams and hospital administrators now evaluate imaging investments not solely on image quality but on interoperability, throughput, patient comfort, and downstream impact on multidisciplinary care pathways.

Clinical adoption is being accelerated by tighter integration between imaging modalities and cloud-enabled data management, while value-based care imperatives drive institutions to quantify diagnostic yield and follow-up reductions. At the same time, regulatory scrutiny and reimbursement dynamics influence procurement timelines and capital planning. Therefore, leaders must synthesize technical performance with clinical workflows and fiscal realities when assessing cancer imaging strategies.

This introduction frames the subsequent analysis by focusing on the interplay between modality innovation, technology convergence, and stakeholder requirements. It underscores the necessity for health systems and diagnostic providers to align selection criteria with long-term clinical objectives and operational resilience, and it sets the stage for deeper examination of industry shifts, policy impacts, segmentation insights, and regional dynamics that shape procurement and adoption decisions.

Observing modality advances, computational augmentation, and care pathway integration reshaping diagnostic workflows and procurement philosophies in oncology imaging

The cancer imaging landscape is undergoing transformative shifts driven by three parallel vectors: modality innovation, computational augmentation, and care pathway integration. Modality innovation continues to refine spatial and temporal resolution across CT and MRI platforms while hybrid systems and advances in detector technology reduce scan times and improve lesion conspicuity. Concurrently, computational augmentation through artificial intelligence and three-dimensional visualization tools enhances lesion detection, automates quantitative measurements, and standardizes reporting across sites, thereby improving diagnostic consistency and enabling accelerated decision-making.

Care pathway integration is aligning imaging outputs with multidisciplinary oncology workflows. Radiology reports increasingly feed structured data into tumor boards, surgical planning, and radiation therapy contouring systems. This integration reduces handoff friction and shortens time-to-treatment for complex cases. Additionally, manufacturers and providers are prioritizing patient-centric features such as open-bore MRI designs and faster CT protocols to improve tolerability and throughput, which in turn impacts scheduling efficiency and downstream revenue cycles.

Finally, procurement and service models are shifting toward outcome-oriented contracts and managed equipment services that bundle uptime guarantees, software updates, and AI tool access. These arrangements reflect a broader industry move away from transactional purchasing and toward partnerships that share operational risk and align vendor incentives with clinical outcomes and system efficiency.

Assessment of tariff-driven procurement pressures and supply chain resilience strategies reshaping sourcing, financing, and lifecycle planning across imaging providers in 2025

The introduction of new tariff measures in 2025 has amplified supply chain scrutiny within the medical imaging ecosystem, prompting procurement leaders to evaluate component sourcing, manufacturing footprints, and total cost of ownership assumptions. Tariffs on imported imaging components and capital equipment have placed upward pressure on procurement budgets, encouraging buyers to revisit maintenance strategies, extend equipment refresh cycles, and explore alternative financing structures that mitigate immediate capital strain. This fiscal pressure has also stimulated wider consideration of regional manufacturing and localized supply networks to reduce exposure to cross-border trade policy volatility.

In response, some vendors have accelerated supplier diversification and nearshoring initiatives, relocating critical supply chain nodes closer to major end markets to limit tariff pass-through and shorten lead times. These strategic shifts, however, require substantial lead-time investments and complex qualification of new suppliers to preserve image quality and device safety. Meanwhile, clinical providers have adapted by emphasizing modular upgrades and software-driven performance enhancements that defer full-platform replacement while still delivering incremental clinical benefits.

Regulatory authorities and reimbursement payers have begun assessing whether tariff-induced cost changes necessitate updates to equipment valuation frameworks and procurement guidelines. Hospitals and imaging centers are increasingly negotiating total lifecycle service agreements and consumables bundling to stabilize operational expenses amid pricing uncertainty. As a result, stakeholders are prioritizing resilient procurement strategies, strengthening vendor partnerships, and integrating scenario-based financial planning to preserve access to advanced imaging capabilities while managing near-term cost impacts.

Granular segmentation insights linking product types, clinical applications, enabling technologies, and end user priorities to inform modality selection and service model design

Understanding segmentation nuances is essential for aligning product selection and service models with clinical and operational objectives. When considering product type, computed tomography offerings range from cone beam CT optimized for high-resolution localized imaging to dual source CT that enhances temporal resolution and multi slice CT systems that balance speed and image quality, while digital radiography options include charged coupled device and flat panel detector technologies that affect dose efficiency and workflow integration. Magnetic resonance imaging is available in closed configurations that prioritize high-field diagnostic clarity, extremity MRI systems that deliver focused musculoskeletal imaging, and open MRI solutions that improve patient comfort. Positron emission tomography remains differentiated by PET CT hybrids that merge anatomical and metabolic data and PET MRI hybrids that combine superior soft-tissue contrast with molecular imaging. Ultrasound continues to serve diverse clinical needs through Doppler analysis for vascular assessment, two-dimensional imaging for routine evaluation, and three-dimensional or four-dimensional analyses that support volumetric assessment and procedural guidance.

Applications drive modality prioritization, with specific clinical use cases such as breast cancer screening and diagnostic workup favoring high-resolution mammographic and hybrid solutions, colorectal cancer surveillance requiring cross-sectional imaging and contrast-enhanced techniques, lung cancer pathways depending heavily on low-dose CT protocols and PET-based metabolic characterization, and prostate cancer management leveraging multiparametric MRI and targeted ultrasound interventions. Technology choices further refine value propositions: artificial intelligence supports computer aided detection, computer aided diagnosis, and workflow management that together improve throughput and diagnostic reliability; contrast imaging modalities rely on CT, MRI, and ultrasound agents to enhance lesion delineation and functional assessment; hybrid imaging configurations such as PET CT, PET MRI, and SPECT CT bring complementary diagnostic dimensions; and three-dimensional visualization techniques including maximum intensity projection, surface rendering, and volume rendering facilitate surgical planning and radiotherapy contouring.

End users present distinct procurement and usage patterns. Academic research institutes prioritize extensibility, advanced analytic capabilities, and study-grade data capture. Clinics and diagnostic imaging centers favor throughput, cost-effectiveness, and integrated reporting that streamlines patient throughput. Hospitals require scalable systems that balance acute care demands with outpatient diagnostic volumes and emphasize serviceability and contract support. Recognizing these segmentation layers enables supply-side and clinical leaders to match modality selection and service models to institutional priorities, ensuring investments support diagnostic yield, operational efficiency, and clinical workflow integration.

Regional adoption contrasts and vendor go-to-market adaptations driven by differing healthcare structures, regulatory environments, and infrastructure priorities

Regional dynamics significantly influence adoption curves, vendor strategies, and service delivery models across the cancer imaging landscape. In the Americas, demand is shaped by integrated health systems and large hospital networks that emphasize interoperability, reimbursement clarity, and lifecycle service agreements; manufacturers often pursue strategic partnerships with regional service providers to ensure uptime and to support complex hybrid installations. Europe, the Middle East & Africa features heterogeneous regulatory environments and procurement mechanisms that create varied adoption pathways; this region commonly balances centralized academic centers driving early adoption with decentralized clinics prioritizing cost-effective modalities and modular upgrades, while geopolitical factors and uneven infrastructure investment can accelerate interest in mobile and scalable imaging solutions.

Asia-Pacific continues to exhibit rapid investment in capacity expansion and technology adoption driven by population-scale screening programs and growing cancer care networks, leading to a diverse landscape where high-volume urban centers adopt cutting-edge hybrid and AI-enabled systems while secondary markets prioritize robust, easy-to-service platforms. Vendors respond by tailoring go-to-market approaches and financing models to regional needs, offering managed service options, training programs, and localized support hubs. These regional contrasts influence product development roadmaps and aftermarket strategies, encouraging vendors to design platforms that balance global technical standards with configurable deployment options for distinct regulatory and clinical contexts.

Competitive differentiation through combined hardware excellence, software ecosystems, and service models that prioritize clinical validation and operational continuity

Industry participants are increasingly differentiating through integrated ecosystems that combine hardware excellence with software services, data analytics, and comprehensive maintenance programs. Established imaging manufacturers continue to invest in detector technologies, magnet design, and hybrid modality engineering while also accelerating partnerships and in-house development of AI algorithms and visualization suites to extend value beyond raw image generation. Concurrently, a growing cohort of specialist technology firms focuses on AI-enabled detection, workflow orchestration, and cloud-native image management, pressuring traditional vendors to broaden their software and service portfolios.

Strategic activity includes partnerships for clinical validation, regulatory submissions for AI tools, and the expansion of service footprints to support complex hybrid installations and bundled consumables. Competitive positioning increasingly depends on demonstrating clinical utility through peer-reviewed evidence and cross-site validation studies that show reproducible improvements in diagnostic accuracy and workflow efficiency. Additionally, vendors that offer flexible financing, comprehensive training, and outcome-linked service agreements gain traction among large health systems seeking to align vendor incentives with clinical performance and operational uptime.

Actionable strategic priorities for vendors and providers focusing on modular platforms, validated AI, flexible procurement, and resilient regional service capabilities

Industry leaders can act decisively to capitalize on clinical demand and policy shifts by pursuing several interlocking strategies. First, prioritize modular product architectures and software-upgradeable platforms that allow customers to extend system life and adopt new analytic capabilities without full hardware replacement. Second, invest in clinically validated AI tools and rigorous multi-center studies that demonstrate measurable improvements in lesion detection, reporting consistency, and workflow efficiency, thereby smoothing regulatory pathways and buyer acceptance.

Third, develop flexible procurement options including managed service agreements, subscription licensing, and outcome-linked contracts that align vendor revenue models with customer operational goals. Fourth, strengthen regional service networks and spare-part ecosystems to mitigate tariff and supply chain risk, and consider nearshoring critical component manufacturing where feasible to stabilize lead times and costs. Fifth, design training and implementation programs that embed imaging outputs into multidisciplinary care pathways, ensuring that new capabilities translate into faster clinical decisions and measurable patient benefit. Executing these priorities will require cross-functional coordination among R&D, regulatory affairs, commercial teams, and clinical partners to deliver cohesive product and service propositions that meet the evolving needs of oncologic care providers.

Transparent mixed-methods approach combining stakeholder interviews, clinical literature review, and comparative technology assessments to produce actionable imaging insights

This research synthesized primary and secondary intelligence to produce evidence-based insights and practical recommendations. Primary inputs included structured interviews with clinical radiologists, imaging center directors, procurement officers, and device service managers to capture operational realities, modality priorities, and procurement constraints. These qualitative inputs were triangulated with technical literature, peer-reviewed clinical studies, regulatory communications, and manufacturer product specifications to ensure alignment with current clinical evidence and device performance claims.

Analytical methods combined thematic analysis of stakeholder interviews with comparative technology assessment frameworks that evaluate image quality, throughput, serviceability, and software integration potential. Supply chain and policy impacts were assessed through scenario planning that considered tariff changes, supplier diversification efforts, and regional manufacturing shifts. Throughout, emphasis remained on verifiable clinical and operational outcomes rather than speculative forecasts, and recommendations were calibrated to align with typical procurement cycles and capital planning horizons across hospital systems and diagnostic providers.

Concluding synthesis emphasizing the necessity of aligning imaging capabilities with clinical pathways, procurement pragmatism, and demonstrated patient benefit

As cancer care increasingly prioritizes early detection, precision staging, and personalized treatment planning, imaging systems will remain central to multidisciplinary oncology pathways. The convergence of advanced modality hardware, hybrid imaging techniques, and computational analytics is reshaping diagnostic capabilities and operational expectations. Providers and vendors who focus on interoperability, validated computational tools, and flexible service models will be best positioned to translate technological advances into measurable clinical gains.

Policy and procurement environments will continue to influence adoption patterns, making supply chain resilience and financing flexibility critical considerations for sustained access to advanced imaging. Ultimately, success will hinge on aligning product capabilities with clinical workflows and outcome metrics, thereby ensuring that investments in imaging technology directly support improved patient pathways and system efficiency. Stakeholders should treat imaging strategy as an integral component of broader oncology program development rather than as an isolated capital decision.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Imaging System Market, by Product Type

  • 8.1. Computed Tomography
    • 8.1.1. Cone Beam Computed Tomography
    • 8.1.2. Dual Source Computed Tomography
    • 8.1.3. Multi Slice Computed Tomography
  • 8.2. Digital Radiography
    • 8.2.1. Charged Coupled Device
    • 8.2.2. Flat Panel Detector
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Closed Magnetic Resonance Imaging
    • 8.3.2. Extremity Magnetic Resonance Imaging
    • 8.3.3. Open Magnetic Resonance Imaging
  • 8.4. Positron Emission Tomography
    • 8.4.1. PET CT
    • 8.4.2. PET MRI
  • 8.5. Ultrasound
    • 8.5.1. Doppler Analysis
    • 8.5.2. Three D Four D Analysis
    • 8.5.3. Two D Analysis

9. Cancer Imaging System Market, by Application

  • 9.1. Breast Cancer
  • 9.2. Colorectal Cancer
  • 9.3. Lung Cancer
  • 9.4. Prostate Cancer

10. Cancer Imaging System Market, by Technology

  • 10.1. Artificial Intelligence
    • 10.1.1. Computer Aided Detection
    • 10.1.2. Computer Aided Diagnosis
    • 10.1.3. Workflow Management
  • 10.2. Contrast Imaging
    • 10.2.1. CT Contrast Agents
    • 10.2.2. MRI Contrast Agents
    • 10.2.3. Ultrasound Contrast Agents
  • 10.3. Hybrid Imaging
    • 10.3.1. PET CT Hybrid
    • 10.3.2. PET MRI Hybrid
    • 10.3.3. SPECT CT Hybrid
  • 10.4. Three D Visualization
    • 10.4.1. Max Intensity Projection
    • 10.4.2. Surface Rendering
    • 10.4.3. Volume Rendering

11. Cancer Imaging System Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Clinics
  • 11.3. Diagnostic Imaging Centers
  • 11.4. Hospitals

12. Cancer Imaging System Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Imaging System Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Imaging System Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Imaging System Market

16. China Cancer Imaging System Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Agfa-Gevaert N.V.
  • 17.6. Agilent Technologies Inc.
  • 17.7. Analogic Corporation
  • 17.8. Barco NV
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories Inc.
  • 17.11. Bracco Imaging S.p.A.
  • 17.12. Canon Medical Systems Corporation
  • 17.13. Carestream Health Inc.
  • 17.14. Danaher Corporation
  • 17.15. Delphinus Medical Technologies Inc.
  • 17.16. Elekta AB
  • 17.17. Esaote S.p.A.
  • 17.18. F. Hoffmann-La Roche Ltd.
  • 17.19. FUJIFILM Holdings Corporation
  • 17.20. GE HealthCare Technologies Inc.
  • 17.21. Hitachi, Ltd.
  • 17.22. Hologic Inc.
  • 17.23. IBA Ion Beam Applications SA
  • 17.24. Illumina Inc.
  • 17.25. Konica Minolta Inc.
  • 17.26. Koninklijke Philips N.V.
  • 17.27. Lantheus Holdings Inc.
  • 17.28. Samsung Medison Co., Ltd.
  • 17.29. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMAGING SYSTEM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONE BEAM COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DUAL SOURCE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MULTI SLICE COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CHARGED COUPLED DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY FLAT PANEL DETECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLOSED MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY EXTREMITY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY OPEN MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DOPPLER ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D FOUR D ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TWO D ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTER AIDED DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY WORKFLOW MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CT CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MRI CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY PET MRI HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SPECT CT HYBRID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY MAX INTENSITY PROJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY SURFACE RENDERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY VOLUME RENDERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL CANCER IMAGING SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 272. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 273. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 274. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 276. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 279. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 280. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 282. GCC CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION CANCER IMAGING SYSTEM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY COMPUTED TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY DIGITAL RADIOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY ULTRASOUND, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY CONTRAST IMAGING, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY HYBRID IMAGING, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS CANCER IMAGING SYSTEM MARKET SIZE, BY THREE D VISUALIZATION, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS CANCER IM